Hot Features
プレミアム
Biomea Fusion Inc (BMEA)
NASDAQ
ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bi... Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. 詳細を表示
Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea preparing icovamenib for late-stage clinical development2025 corporate update to be...
New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight reduction and 43% increase in lean muscle mass...
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...
Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient populationBest response...
REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...
In preclinical experiments, icovamenib enhanced beta cell function and responsiveness of human islets to GLP-1-based therapies. These effects were associated with an increase in the expression...
Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemiaBMF-500 showed a favorable safety and...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.4 | 10.0502512563 | 3.98 | 4.59 | 3.8 | 696812 | 4.2970037 | CS |
| 4 | 0.43 | 10.8860759494 | 3.95 | 4.59 | 3.64 | 825934 | 4.03986043 | CS |
| 12 | -4.62 | -51.3333333333 | 9 | 9.26 | 3.64 | 863794 | 5.35681629 | CS |
| 26 | -1.13 | -20.5081669691 | 5.51 | 13.07 | 3.64 | 853776 | 7.07861674 | CS |
| 52 | -12.37 | -73.8507462687 | 16.75 | 20.21 | 3.61 | 1001078 | 9.16660353 | CS |
| 156 | -2.3 | -34.4311377246 | 6.68 | 43.69 | 2.84 | 658515 | 14.49245209 | CS |
| 260 | -15.62 | -78.1 | 20 | 43.69 | 2.84 | 551838 | 14.38865129 | CS |
Monksdream
5月前
Zraced1
8月前
giveit2me
1年前
Invest-in-America
2年前
Invest-in-America
2年前
TheFinalCD
2年前
Invest-in-America
2年前
Bbradley8
2年前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
